Aurobindo Pharma has reported results for second quarter ended September 30, 2023 (Q2FY24).
The company has reported over 2-fold jump in its net profit at Rs 415.74 crore for the quarter under review as compared to Rs 164.63 crore for the same quarter in the previous year. Total income of the company increased by 36.54% at Rs 2,735.84 crore for Q2FY24 as compared to Rs 2,003.64 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 83.23% rise in its net profit at Rs 751.94 crore for Q2FY24 as compared to Rs 410.37 crore for the same quarter in the previous year. Total income of the company increased by 27.77% at Rs 7,406.40 crore for Q2FY24 as compared to Rs 5,796.56 crore for the corresponding quarter previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: